Plasma branched-chain amino acid concentrations in individuals without cardiovascular diseases versus patients diagnosed with hypertension and coronary artery disease

Aim . Branched-chain amino acids (BCAAs) have been postulated as potential indicators of cardiovascular risk. The objective this study was to explore the relationship between plasma BCAAs and different stages disorders. Material methods In our cross-sectional study, (valine, leucine isoleucine) in individuals without diseases (CVDs) (nonCVD group, total n=27, with n=16 healthy, but metabolic disorders) were compared patients diagnosed CVDs [CVD n=109, being n=61 hypertension (n=31 signs beginning myocardial remodeling) n=48 coronary artery disease (CAD)]. Results. concentration significantly higher group healthy (p<0.05 for all tested): valine 238.7 [219.6; 267.0] μM non-CVD 261.2 [233.8; 298.7] CVD group; 134.8 [122.4; 153.2] 146.8 [129.0; 166.6] μM, respectively; isoleucine 72.7 [65.3; 84.4] 81.7 [68.0; 96.2] respectively. Leucine levels minimal participant subgroup maximal IBS patient subgroup. No statistically significant differences concentrations found subgroups CAD. Significant increases observed CAD follows: 256.3 [219.0; 297.9] 261.7 [236.5; 307.5] 141.8 [123.5; 154.1 [134.7; 172.7] respectively, 72.8 [65.7; 94.0] 85.7 [74.9; 101.7] profiles participants disorders had “good” diagnostic accuracy area under receiver operating characteristics curve 0.72, 0.70 valine, isoleucine, Conclusion are elevated severity disorder exhibit early independent disease.